It Seems St. Jude Medical, Inc. Will Go Down. Had Bearish Options Activity

 It Seems St. Jude Medical, Inc. Will Go Down. Had Bearish Options Activity

In today’s session St. Jude Medical, Inc. (STJ) recorded an unusually high (483) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the October, 2016 put, expecting serious STJ decrease. With 483 contracts traded and 69344 open interest for the Oct, 16 contract, it seems this is a quite bearish bet. The option with symbol: STJ161021P00065000 closed last at: $0.3 or 14.3% down. About 487,078 shares traded hands. St. Jude Medical, Inc. (NYSE:STJ) has risen 45.38% since March 2, 2016 and is uptrending. It has outperformed by 37.13% the S&P500.

Analysts await St. Jude Medical, Inc. (NYSE:STJ) to report earnings on October, 19. They expect $1.01 EPS, up 4.12% or $0.04 from last year’s $0.97 per share. STJ’s profit will be $286.63M for 19.82 P/E if the $1.01 EPS becomes a reality. After $1.06 actual EPS reported by St. Jude Medical, Inc. for the previous quarter, Wall Street now forecasts -4.72% negative EPS growth.

St. Jude Medical, Inc. (NYSE:STJ) Ratings Coverage

Out of 20 analysts covering St. Jude Medical Inc. (NYSE:STJ), 4 rate it a “Buy”, 0 “Sell”, while 16 “Hold”. This means 20% are positive. St. Jude Medical Inc. has been the topic of 45 analyst reports since July 21, 2015 according to StockzIntelligence Inc. The stock of St. Jude Medical, Inc. (NYSE:STJ) earned “Neutral” rating by Wedbush on Friday, July 15. The firm has “Hold” rating by Needham given on Friday, April 29. The rating was maintained by BTIG Research on Sunday, September 6 with “Buy”. RBC Capital Markets maintained it with “Sector Perform” rating and $75 target price in Thursday, July 23 report. RBC Capital Markets maintained the shares of STJ in a report on Thursday, October 22 with “Sector Perform” rating. SunTrust initiated St. Jude Medical, Inc. (NYSE:STJ) on Friday, January 8 with “Buy” rating. Stifel Nicolaus downgraded the shares of STJ in a report on Thursday, October 22 to “Hold” rating. The stock of St. Jude Medical, Inc. (NYSE:STJ) earned “Neutral” rating by BTIG Research on Monday, April 18. SunTrust downgraded the shares of STJ in a report on Tuesday, May 10 to “Neutral” rating. The firm has “Equal-Weight” rating given on Monday, May 2 by Morgan Stanley.

According to Zacks Investment Research, “St. Jude Medical, Inc. is dedicated to making life better for cardiac, neurological and chronic pain patients worldwide through excellence in medical device technology and services. The Company has five major focus areas that include cardiac rhythm management, atrial fibrillation, cardiac surgery, cardiology and neuromodulation.”

Insitutional Activity: The institutional sentiment decreased to 0.86 in Q2 2016. Its down 0.13, from 0.99 in 2016Q1. The ratio is negative, as 73 funds sold all St. Jude Medical, Inc. shares owned while 218 reduced positions. 108 funds bought stakes while 143 increased positions. They now own 256.31 million shares or 7.42% more from 238.60 million shares in 2016Q1.
Kcg Hldg has 11,149 shares for 0.02% of their US portfolio. Jnba Financial Advisors has 0.01% invested in the company for 574 shares. Tt Intl, a United Kingdom-based fund reported 70,000 shares. Cap Incorporated Ca accumulated 28,390 shares or 0.27% of the stock. Neuberger Berman Group Limited Liability, a New York-based fund reported 25,127 shares. Weatherly Asset Mgmt Lp holds 6,581 shares or 0.11% of its portfolio. Ikos Cif Ltd owns 996 shares or 0.27% of their US portfolio. The New Jersey-based Hanlon Investment has invested 0.41% in St. Jude Medical, Inc. (NYSE:STJ). Baldwin Brothers Ma owns 115 shares or 0% of their US portfolio. Macquarie Group Limited owns 93,121 shares or 0.01% of their US portfolio. Plante Moran Ltd Limited Liability Company reported 381 shares or 0.02% of all its holdings. New York State Common Retirement Fund reported 776,491 shares or 0.09% of all its holdings. Profund Lc reported 11,882 shares or 0.05% of all its holdings. Moreover, Bb&T has 0.01% invested in St. Jude Medical, Inc. (NYSE:STJ) for 6,287 shares. National Planning reported 2,543 shares or 0.02% of all its holdings.

St. Jude Medical, Inc. is focused on the development, manufacture and distribution of cardiovascular medical devices for the global cardiac rhythm management, cardiovascular and atrial fibrillation therapy areas, and interventional pain therapy and neurostimulation devices for the management of chronic pain and movement disorders. The company has a market cap of $22.72 billion.

STJ Company Profile

St. Jude Medical, Inc., incorporated on May 12, 1976, is focused on the development, manufacture and distribution of cardiovascular medical devices for the global cardiac rhythm management, cardiovascular and atrial fibrillation therapy areas, and interventional pain therapy and neurostimulation devices for the management of chronic pain and movement disorders. The Company’s product categories include tachycardia implantable cardioverter defibrillator (ICD) systems; atrial fibrillation (AF) products (electrophysiology (EP) introducers and catheters, advanced cardiac mapping, navigation and recording systems and ablation systems); bradycardia pacemaker (pacemaker) systems; vascular products (vascular closure products, pressure measurement guidewires, optical coherence tomography (OCT) imaging products, vascular plugs, heart failure monitoring devices and other vascular accessories); structural heart products (heart valve replacement and repair products and structural heart defect devices); neuromodulation products (spinal cord stimulation and radiofrequency ablation to treat chronic pain and deep brain stimulation to treat movement disorders), and Thoratec products (ventricular assist devices and percutaneous heart pumps).

More important recent St. Jude Medical, Inc. (NYSE:STJ) news were published by: Reuters.com which released: “EU ruling on $25 billion Abbott, St. Jude deal due by November 9” on October 04, 2016, also Businesswire.com published article titled: “St. Jude Medical Announces European Full Market Release of EnSite Precision …”, Businesswire.com published: “St. Jude Medical Announces FDA Approval of BurstDR Stimulation, a New Superior …” on October 04, 2016. More interesting news about St. Jude Medical, Inc. (NYSE:STJ) was released by: Wsj.com and their article: “St. Jude Medical Sues Short Seller Over Device Allegations” with publication date: September 07, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment